AMSilk expands distribution network in Asia
Advertisement
AMSilk GmbH continuously extends its international distribution network. After having finalized distribution agreements for the main European markets in the first half of 2016, AMSilk now succeeded in winning a renowned distribution partner for the Asian market. From now on, the Korean-based company Hanjoo C&C will cover the distribution of the AMSilk products Silkbeads (microparticles) and Silkgel (hydrogel) in Korea. These products are functional ingredients used in cosmetics and personal care applications.
“After having implemented cooperations with our three new distributors RAHN, ZEUS and BIOCHIM for most parts of the European market, we are now progressing in our internationalization strategy. With Hanjoo we have won a strong new partner for selling our high-performance products in the advanced and innovative Korean market. Several cosmetic applications such as creams, serums and facial masks containing our silk biopolymers are already being marketed successfully in Asian countries. Thus, we see a huge potential for our products in the Asian market”, says Jens Klein, CEO of AMSilk.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Diversa and Celunol Complete Merger to Create Verenium Corporation - Focus on Cellulosic Biofuel Development and Commercialization of Diversified Industrial Enzyme Portfolio
Evidence of activity seen in new data from ASA404 prostate cancer trial
Chromos shareholders approve acquisition of Targeted Molecules Corporation and financing terms
Nobilon and NVI co-developing RSV vaccine
InterMed Discovery achieves Proof-of-Principle for IMD-026260 - Small molecule anti-cancer drug candidate based on Hif-1 modulation
Large international study finds memory in adults impacted by versions of 4 genes - Second study identifies brain-development genes associated with intracranial volume
Evolva acquires resveratrol programme from Fluxome
Network that plays crucial role in cell function and disease
Celera Genomics Receives NIH Grant to Develop and Commercialize Avian Flu Diagnostic Test